Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ARIX BIOSCIENCE PLC Report Publication Announcement 2021

Feb 11, 2021

4968_rns_2021-02-11_aaaff8cd-8ab6-4c94-b3ce-4cc2e7836355.html

Report Publication Announcement

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

Arix Bioscience PLC (ARIX)

Notice of Results

11-Feb-2021 / 07:00 GMT/BST

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

The issuer is solely responsible for the content of this announcement.


Arix Bioscience plc

Notice of Results

LONDON, 11 February 2021: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, will announce its annual results for the year ended 31 December 2020, on Tuesday 9th March 2021.

Arix will host a virtual analyst presentation on the same day, at 12:00pm GMT, followed by a Q&A session, accessible via conference call or webcast. The webcast of the presentation will be available on the Company's investor relations website at https://arixbioscience.com/investor-relations/events-presentations.

For details of the conference call please contact [email protected].

[ENDS]

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

[email protected]

Optimum Strategic Communications

Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

[email protected]

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com


ISIN: GB00BD045071
Category Code: NOR
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 93411
EQS News ID: 1167627
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1167627&application_name=news&site_id=fca